Company news
NeuroSense Therapeutics Ltd. news in 2026
NeuroSense Therapeutics Ltd.'s news releases, calls and decks from 2026, newest first.
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
November 2, 2026
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
October 29, 2026
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
October 19, 2026
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
October 13, 2026
NeuroSense Provides Update on Nasdaq Listing Compliance
October 2, 2026
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
September 28, 2026
NeuroSense Provides Business Update and Progress for the First Half of 2026
September 25, 2026
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
August 31, 2026
NeuroSense Issues CEO Letter to Shareholders
August 13, 2026
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
August 6, 2026
NeuroSense Advances PrimeC toward New Drug Submission to Health Canada for ALS
July 23, 2026
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
July 22, 2026
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
July 6, 2026
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
June 29, 2026
NeuroSense Therapeutics Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
June 25, 2026
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
June 25, 2026
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
June 22, 2026
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
June 11, 2026
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
June 8, 2026
NeuroSense Announces Pricing of Insider-Led PIPE Financing
April 27, 2026
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
April 6, 2026
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
April 2, 2026
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
March 31, 2026
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
March 23, 2026
Correction: NeuroSense
March 17, 2026
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
March 15, 2026
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
March 8, 2026
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
February 18, 2026
NeuroSense Expands Global IP Protection Strategy with Granted Australian Patent Covering PrimeC Composition
February 10, 2026
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
February 9, 2026
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
January 21, 2026
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
January 8, 2026
Decks in 2026
- Investor Presentation (July 2026)
Investor deck · 32 slides · July 2026